At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed papillary or follicular thyroid cancer (including hurthle cell, insular, columnar cell, tall cell variants)
- ✓Metastatic disease present
- ✓At least 1 measurable lesion ≥20 mm by conventional imaging or ≥10 mm by spiral CT
- ✓Unresponsive to prior radioiodine therapy
- ✕No prior radiotherapy to the only or measured tumor lesion
- ✕No symptomatic congestive heart failure
- ✕No unstable angina pectoris
- ✕No cardiac arrhythmia
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma
In Brief
A Phase 2 clinical trial evaluating Bortezomib for Insular Thyroid Cancer and 5 related conditions. Completed, enrolled 24 participants across 9 sites.
Detailed Summary
This phase II trial is studying how well bortezomib works in treating patients with metastatic thyroid cancer that did not respond to radioactive iodine therapy. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
Study Details
Timeline
Interventions
Administered IV at the dose of 1.3 mg/m\^2 on a twice-weekly schedule for 2 consecutive weeks on days 1, 4, 8, and 11, followed by a 10 day rest period on days 12-21 (one cycle). In the absence of clinical progression, treatment continued for a minimum of 4 treatment cycles (or 12 weeks).